CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.

CD19 CAR T cell therapy demonstrated acceptable safety and significant clinical improvements in six patients with treatment-refractory seropositive rheumatoid arthritis, with a median 34% DAS28-CRP reduction.

• Why it matters: Effective treatments for severe, refractory rheumatoid arthritis are limited, and novel therapies are needed to target underlying immune mechanisms and improve patient outcomes.
• What they did: Six patients received a single infusion of autologous CD19 CAR T cells after stopping immunosuppressants, with safety and efficacy monitored over 36-52 weeks, focusing on adverse events and immune responses.
• The result: The therapy caused manageable cytokine release syndrome, depleted CD19+ B cells, reduced autoantibodies, and improved disease activity, supporting further clinical development.